Pediatrix Medical (MD) EBITDA Margin (2009 - 2026)

Pediatrix Medical has disclosed EBITDA Margin across 18 years of filings, most recently posting 6.1% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 140.0% year-over-year to 6.1%; the TTM figure through Mar 2026 stood at 9.04% (up 1311.0% YoY), while the FY2025 annual figure was 8.73%, up 1359.0% from the prior year.
• EBITDA Margin declined to 6.1% in Q1 2026, from 6.85% in the prior quarter.
• Over the last five years, EBITDA Margin for MD reached as high as 14.61% in Q3 2025 and fell as low as 30.3% in Q2 2024.
• The 5-year median for EBITDA Margin is 5.33% (2022), against an average of 1.27%.
• Annual changes were most pronounced in 2024 — EBITDA Margin plunged 3588 bps — and 2025, when it soared 3877 bps.
• A 5-year view of EBITDA Margin shows it stood at 5.84% in 2022, then tumbled by 524 bps to 24.77% in 2023, then jumped by 124 bps to 5.9% in 2024, then advanced by 16 bps to 6.85% in 2025, then decreased by 11 bps to 6.1% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 6.1%, 6.85%, and 14.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.